Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Vertex Reports Third Quarter 2022 Financial Results
October 27, 2022 4:01 PM EDTProduct revenue of $2.33 billion, an 18% increase compared to Q3 2021
Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion
Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities:
Initiating global exa-cel regulatory submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Initiated Phase 3 clinical studies of VX-548, a novel, selective NaV1.8 inhibitor, in acute pain
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third... More
